Utility of serum free light chain ratio in response definition in patients with multiple myeloma

Nadine Abdallah; Prashant Kapoor; David L. Murray; Francis K. Buadi; David Dingli; Angela Dispenzieri; Morie A. Gertz; Ronald S. Go; Wilson I. Gonsalves; Suzanne R. Hayman; Taxiarchis V. Kourelis; Martha Q. Lacy; Nelson Leung; John A. Lust; Eli Muchtar; Rahma Warsame; Robert A. Kyle; S. Vincent Rajkumar; Shaji K. Kumar

doi:10.1182/bloodadvances.2019001099

Utility of serum free light chain ratio in response definition in patients with multiple myeloma

Nadine Abdallah, Prashant Kapoor, David L. Murray, Francis K. Buadi, David Dingli, Angela Dispenzieri, Morie A. Gertz, Ronald S. Go, Wilson I. Gonsalves, Suzanne R. Hayman, Taxiarchis V. Kourelis, Martha Q. Lacy, Nelson Leung, John A. Lust, Eli Muchtar, Rahma Warsame, Robert A. Kyle, S. Vincent Rajkumar, Shaji K. Kumar

Hematology

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	322-326
Number of pages	5
Journal	Blood Advances
Volume	4
Issue number	2
DOIs	https://doi.org/10.1182/bloodadvances.2019001099
State	Published - Jan 28 2020

ASJC Scopus subject areas

Hematology

Access to Document

10.1182/bloodadvances.2019001099

Cite this

Abdallah, N., Kapoor, P., Murray, D. L., Buadi, F. K., Dingli, D., Dispenzieri, A., Gertz, M. A., Go, R. S., Gonsalves, W. I., Hayman, S. R., Kourelis, T. V., Lacy, M. Q., Leung, N., Lust, J. A., Muchtar, E., Warsame, R., Kyle, R. A., Rajkumar, S. V., & Kumar, S. K. (2020). Utility of serum free light chain ratio in response definition in patients with multiple myeloma. Blood Advances, 4(2), 322-326. https://doi.org/10.1182/bloodadvances.2019001099

Abdallah, N, Kapoor, P, Murray, DL, Buadi, FK, Dingli, D , Dispenzieri, A , Gertz, MA, Go, RS, Gonsalves, WI, Hayman, SR, Kourelis, TV , Lacy, MQ, Leung, N, Lust, JA, Muchtar, E, Warsame, R, Kyle, RA, Rajkumar, SV & Kumar, SK 2020, 'Utility of serum free light chain ratio in response definition in patients with multiple myeloma', Blood Advances, vol. 4, no. 2, pp. 322-326. https://doi.org/10.1182/bloodadvances.2019001099

@article{a981e7dfec31405ca4ad417731775012,

title = "Utility of serum free light chain ratio in response definition in patients with multiple myeloma",

author = "Nadine Abdallah and Prashant Kapoor and Murray, {David L.} and Buadi, {Francis K.} and David Dingli and Angela Dispenzieri and Gertz, {Morie A.} and Go, {Ronald S.} and Gonsalves, {Wilson I.} and Hayman, {Suzanne R.} and Kourelis, {Taxiarchis V.} and Lacy, {Martha Q.} and Nelson Leung and Lust, {John A.} and Eli Muchtar and Rahma Warsame and Kyle, {Robert A.} and Rajkumar, {S. Vincent} and Kumar, {Shaji K.}",

note = "Funding Information: Conflict-of-interest disclosure: P.K. received research funding from Takeda Pharmaceuticals, Celgene, and Amgen. A.D. received research funding from Celgene, Millennium Pharmaceuticals, Pfizer, and Janssen, and received a travel grant from Pfizer. M.A.G. served as a consultant for Millennium Pharmaceuticals and received honoraria from Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Novartis, GlaxoSmithKline, Prothena, Ionis Pharmaceuticals, and Amgen. M.Q.L. received research funding from Celgene. N.L. serves on an advisory board for Takeda Pharmaceuticals. S.K.K. served as a consultant for Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Janssen, and Bristol-Myers Squibb, and received research funding from Cel-gene, Millennium Pharmaceuticals, Novartis, Onyx Pharmaceuticals, AbbVie, Janssen, and Bristol-Myers Squibb. The remaining authors declare no competing financial interests.",

year = "2020",

month = jan,

day = "28",

doi = "10.1182/bloodadvances.2019001099",

language = "English (US)",

volume = "4",

pages = "322--326",

journal = "Blood advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "2",

}

TY - JOUR

T1 - Utility of serum free light chain ratio in response definition in patients with multiple myeloma

AU - Abdallah, Nadine

AU - Kapoor, Prashant

AU - Murray, David L.

AU - Buadi, Francis K.

AU - Dingli, David

AU - Dispenzieri, Angela

AU - Gertz, Morie A.

AU - Go, Ronald S.

AU - Gonsalves, Wilson I.

AU - Hayman, Suzanne R.

AU - Kourelis, Taxiarchis V.

AU - Lacy, Martha Q.

AU - Leung, Nelson

AU - Lust, John A.

AU - Muchtar, Eli

AU - Warsame, Rahma

AU - Kyle, Robert A.

AU - Rajkumar, S. Vincent

AU - Kumar, Shaji K.

N1 - Funding Information: Conflict-of-interest disclosure: P.K. received research funding from Takeda Pharmaceuticals, Celgene, and Amgen. A.D. received research funding from Celgene, Millennium Pharmaceuticals, Pfizer, and Janssen, and received a travel grant from Pfizer. M.A.G. served as a consultant for Millennium Pharmaceuticals and received honoraria from Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Novartis, GlaxoSmithKline, Prothena, Ionis Pharmaceuticals, and Amgen. M.Q.L. received research funding from Celgene. N.L. serves on an advisory board for Takeda Pharmaceuticals. S.K.K. served as a consultant for Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Janssen, and Bristol-Myers Squibb, and received research funding from Cel-gene, Millennium Pharmaceuticals, Novartis, Onyx Pharmaceuticals, AbbVie, Janssen, and Bristol-Myers Squibb. The remaining authors declare no competing financial interests.

PY - 2020/1/28

Y1 - 2020/1/28

UR - http://www.scopus.com/inward/record.url?scp=85082104210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85082104210&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2019001099

DO - 10.1182/bloodadvances.2019001099

M3 - Article

C2 - 31978213

AN - SCOPUS:85082104210

SN - 2473-9529

VL - 4

SP - 322

EP - 326

JO - Blood advances

JF - Blood advances

IS - 2

ER -

Utility of serum free light chain ratio in response definition in patients with multiple myeloma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this